Physician profile
Anna Kolano
NPI 1043301427
$979.04
in general payments reported to CMS, 2019-2025
14 companies · $40.00 in 2025
The $40.00 reported for 2025 was less than what a typical General Practice provider received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $647 · 2020: $216 · 2021: $39.26 · 2023: $36.91 · 2025: $40.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $76.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $76.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, Lp | $287.56 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $135.40 | 2019-2020 | |
| Pfizer INC. | $108.13 | 2019-2020 | |
| Kaleo, INC. | $77.53 | 2019-2023 | Auvi-Q |
| Takeda Pharmaceuticals U.S.A., INC. | $62.38 | 2019-2020 | |
| Adlon Therapeutics L.P. | $58.03 | 2019-2021 | |
| Tris Pharma INC | $55.66 | 2019-2020 | |
| Sanofi Pasteur INC. | $55.09 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $43.24 | 2019-2023 | Gardasil 9, Rotateq, Vaxelis |
| Mission Pharmacal Company | $28.86 | 2019 | |
| Sobi, INC | $18.98 | 2020 | |
| Mylan Pharmaceuticals INC. | $17.22 | 2019 | |
| Arbor Pharmaceuticals, INC. | $16.36 | 2019 | |
| Aytu Biopharma, INC. | $14.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Kolano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.